Recommendation of the President – Tremfya (guselkumab)
On 17 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 195/2025 on the reimbursement of the medicinal product Tremfya (guselkumab) under the B. 55 drug program. “Treatment of patients with ulcerative colitis (UC) (ICD-10 K51)”